FDA Approves RCC Drug, Prostate Cancer and Smoking Link: April News Roundup

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD

July 21st 2025

Subcutaneous Daratumumab Approved by EC in Smoldering Multiple Myeloma

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Ariana Pelosci

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Results from the AQUILA trial led to the approval of subcutaneous daratumumab for patients with smoldering multiple myeloma at risk of developing the disease.

Jorge Nieva, MD

July 14th 2025

European Commission Grants Marketing Authorization to Obe-Cel in R/R B-ALL

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

$Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.$

Novel Cancer Vaccine Combos Show Efficacy, Safety in Late-Stage Melanoma

Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

The SCIB1/iSCIB1+ cancer vaccines plus nivolumab and ipilimumab improved responses vs nivolumab and ipilimumab alone in patients with melanoma.

July 22nd 2025

DB-1310 Earns FDA Fast Track Designation in EGFR-Mutant Nonsquamous NSCLC

The SCIB1/iSCIB1+ cancer vaccines plus nivolumab and ipilimumab improved responses vs nivolumab and ipilimumab alone in patients with melanoma.

Related Content

Roman Fabbricatore

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Support for the regulatory decision follows data from a phase 1/2a clinical trial assessing the agent in EGFR-mutant NSCLC at the 2025 ASCO Annual Meeting.

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD

July 21st 2025

Subcutaneous Daratumumab Approved by EC in Smoldering Multiple Myeloma

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Ariana Pelosci

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Results from the AQUILA trial led to the approval of subcutaneous daratumumab for patients with smoldering multiple myeloma at risk of developing the disease.

Jorge Nieva, MD

July 14th 2025

European Commission Grants Marketing Authorization to Obe-Cel in R/R B-ALL

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

$Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.$

Novel Cancer Vaccine Combos Show Efficacy, Safety in Late-Stage Melanoma

Results from the phase 1b/2 FELIX trial demonstrated that obe-cel was efficacious and safe as therapy for relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

July 22nd 2025